GWAS-related meQTLs across different cancer types
We identified 2,214,458 meQTLs that overlap with GWAS linkage disequilibrium (LD) regions (r² ≥ 0.5).
Cancer type
|
QTL type
|
tagSNP
|
Gene position (hg19)
|
Gene
|
p-value
|
|||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BLCA | cis | rs11951515 | 0.508 | rs10059993 | chr5:43598352 | A/G | cg20545087 | chr5:43514988 | C5orf34 | -0.45 | -6.56 | -0.32 | 1.73E-10 | Metabolite levels (X-11787); |
BLCA | cis | rs11630290 | 0.592 | rs1017531 | chr15:64158650 | G/A | cg12036633 | chr15:63758958 | NA | 0.54 | 7.38 | 0.35 | 9.95E-13 | Iris characteristics; |
BLCA | cis | rs9309473 | 1 | rs10187192 | chr2:73713500 | T/C | cg20560298 | chr2:73613845 | ALMS1 | -0.67 | -8.74 | -0.41 | 7.45E-17 | Metabolite levels; |
BLCA | cis | rs10267417 | 0.603 | rs10228558 | chr7:19911915 | A/G | cg05791153 | chr7:19748676 | TWISTNB | 0.55 | 6.52 | 0.32 | 2.18E-10 | Night sleep phenotypes; |
BLCA | cis | rs7100689 | 0.784 | rs10749562 | chr10:82108253 | G/T | cg00277334 | chr10:82204260 | NA | -0.47 | -7.19 | -0.35 | 3.45E-12 | Post bronchodilator FEV1; |
BLCA | cis | rs523522 | 0.962 | rs10849758 | chr12:120971149 | C/T | cg27279351 | chr12:120934652 | DYNLL1 | 0.7 | 10.36 | 0.47 | 2.51E-22 | High light scatter reticulocyte count; |
BLCA | cis | rs7618915 | 0.547 | rs10865973 | chr3:52718154 | A/T | cg18404041 | chr3:52824283 | ITIH1 | -0.38 | -7.43 | -0.36 | 7.04E-13 | Bipolar disorder; |
BLCA | cis | rs7945705 | 0.902 | rs11042152 | chr11:9020987 | C/T | cg09997546 | chr11:8931473 | C11orf17;ST5 | 0.27 | 7.2 | 0.35 | 3.34E-12 | Hemoglobin concentration; |
BLCA | cis | rs977987 | 0.778 | rs1109341 | chr16:75445605 | G/A | cg03315344 | chr16:75512273 | CHST6 | 0.4 | 8.98 | 0.42 | 1.28E-17 | Dupuytren's disease; |
BLCA | cis | rs10861342 | 1 | rs11112380 | chr12:105526695 | C/T | cg23923672 | chr12:105501055 | KIAA1033 | 0.68 | 6.21 | 0.3 | 1.36E-9 | IgG glycosylation; |
BLCA | cis | rs2204008 | 0.837 | rs11168334 | chr12:37961768 | A/G | cg13010199 | chr12:38710504 | ALG10B | 0.61 | 9.97 | 0.46 | 5.77E-21 | Bladder cancer; |
BLCA | cis | rs10883723 | 0.773 | rs11191303 | chr10:104255158 | T/C | cg11453585 | chr10:104263688 | ACTR1A;SUFU | 0.72 | 12.35 | 0.54 | 1.13E-29 | Allergic disease (asthma, hay fever or eczema); |
BLCA | cis | rs2153535 | 0.58 | rs1119690 | chr6:8460660 | G/A | cg07606381 | chr6:8435919 | SLC35B3 | 0.83 | 14.14 | 0.59 | 9.27E-37 | Motion sickness; |
BLCA | cis | rs752010 | 0.695 | rs11210509 | chr1:42109311 | A/G | cg06885757 | chr1:42089581 | HIVEP3 | 0.34 | 7.77 | 0.37 | 7.21E-14 | Lupus nephritis in systemic lupus erythematosus; |
BLCA | cis | rs1707322 | 1 | rs11211243 | chr1:46455433 | G/C | cg03146154 | chr1:46216737 | IPP | 0.43 | 6.19 | 0.3 | 1.6E-9 | Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction); |